Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT00596648 2026-01-13

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

92 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

8 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01927744 2025-11-26

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

55 enrolled 8 charts

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT03498521 2025-11-19

CUPISCO

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT01186861 2025-11-18

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

205 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01221077 2025-11-18

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

88 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT00977470 2025-10-15

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

76 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

492 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT00954226 2025-09-05

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

48 enrolled

Phase 1 Active not recruiting

Salivary Gland Neoplasms

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

237 enrolled

Neoplasms

NCT05442060 2025-08-03

EGFR

Phase 2 Recruiting

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Neoplasms

NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Neoplasms

NCT02991651 2025-05-14

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Phase 1 Terminated

12 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

13 enrolled

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

NCT00954525 2025-05-02

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

14 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00640978 2025-05-01

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2 Terminated

16 enrolled 4 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

49 enrolled 5 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00983307 2025-04-30

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

17 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT00448240 2025-03-18

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Phase 2/3 Terminated

6 enrolled 4 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00503971 2025-03-07

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Phase 1/2 Terminated

33 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT00446225 2025-03-05

EURTAC

Phase 3 Completed

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02535338 2025-03-03

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Phase 1/2 Completed

11 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02424617 2025-02-26

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled 21 charts